Evidence map›Paper›PMID 38784908›Full record

ReviewFrontiers in neurology2024

Stem cell therapies: a new era in the treatment of multiple sclerosis.

Lei Wu, Jing Lu, Tianye Lan, Dongmei Zhang, Hanying Xu, Zezheng Kang, Fang Peng, Jian Wang

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lei WuChangchun University of Chinese Medicine, Changchun, China.
Jing LuThe Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China.
Tianye LanThe Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China.
Dongmei ZhangThe Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China.
Hanying XuChangchun University of Chinese Medicine, Changchun, China.
Zezheng KangChangchun University of Chinese Medicine, Changchun, China.
Fang PengHunan Provincial People's Hospital, Changsha, China.
Jian WangThe Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple Sclerosis (MS) is an immune-mediated condition that persistently harms the central nervous system. While existing treatments can slow its course, a cure remains elusive. Stem cell therapy has gained attention as a promising approach, offering new perspectives with its regenerative and immunomodulatory properties. This article reviews the application of stem cells in MS, encompassing various stem cell types, therapeutic potential mechanisms, preclinical explorations, clinical research advancements, safety profiles of clinical applications, as well as limitations and challenges, aiming to provide new insights into the treatment research for MS.

Indexed as

induced pluripotent stem cellsmultiple sclerosisneural stem cellsstem cell therapystem cell transplantation

Identifiers

PMID38784908
PMCPMC11111935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.